UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Tuesday . The stock had previously closed at $268.71, but opened at $298.14. UCB shares last traded at $298.14, with a volume of 6,061 shares.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UCBJF. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a research report on Monday, December 8th. Barclays restated an “overweight” rating on shares of UCB in a report on Tuesday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of UCB in a report on Monday, September 8th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

UCB Stock Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s 50 day simple moving average is $276.23 and its 200-day simple moving average is $252.05.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.